ArticleFrontiers in oncology2024

Efficacy and safety of pembrolizumab as first-line treatment for advanced non-small cell lung cancer complicated with chronic obstructive pulmonary disease: protocol for a prospective, single-arm, single-center, phase II clinical trial.

Weigang Dong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.